Investors are grappling with concerns about the economy as President Trump's tariff commitments create uncertainty, leading to a mixed performance in global markets after a significant drop in the S&P 500.

The article discusses how low-beta growth stocks like Boston Scientific and Mastercard may perform better as market volatility persists due to Trump's new tariff policies. Trivariate Research provides insights on these stocks amidst investor caution.

Tom Lee, head of research at Fundstrat Global Advisors, suggests that the stock market is currently a buy despite bad news being priced in. He anticipates a potential rally in the upcoming months, positively influenced by market behavior in response to negative reports and President Trump's tariffs.

Stifel has upgraded Scotts Miracle-Gro from hold to buy, predicting a more than 25% upside as the company's stock shows resiliency against economic pressures.

The Nasdaq Composite and other major indices faced significant declines in February, attributed to uncertainties regarding global trade, tariffs imposed by President Trump, and the negative impact on investor sentiment.